Predicting T Cell Recognition: New Insights from Large-Scale Activation Data
A study accepted to ML4H 2025 explores whether sequence-based models trained on large-scale T-cell a...
Publisher
USA
This page provides a limited summary and publisher metadata to support discovery before sending readers to the original article.
Read originalIn-platform summary, original article off-platform
This page presents the title, publisher metadata, and a limited summary excerpt to help users judge relevance first. Full-text reading stays on the publisher's original site.
Summary excerpt
A study accepted to ML4H 2025 explores whether sequence-based models trained on large-scale T-cell a...
Source route
Continue on adaptivebiotech.com
Leave the platform to read the original full article on the publisher site.
Source: Adaptive Biotechnologies
Scope: Industry
Related coverage
More related coverage
Allogene Therapeutics Conference Call
The Investor Relations website contains information about Allogene Therapeutics’s business for stock...
Allogene Therapeutics to Announce Interim Futility Analysis Data from its Pivotal Phase 2 ALPHA3 Trial with Cemacabtagene Ansegedleucel (Cema-Cel) in First-Line Consolidation LBCL on Monday, April 13, 202
The post Allogene Therapeutics to Announce Interim Futility Analysis Data from its Pivotal Phase 2 A...
Idorsia issues invitation to the 2026 Annual General Meeting of Shareholders
Viking Therapeutics to Participate at Upcoming Investor Conferences
Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focu...